Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CANOPY-1
2018-001547-32Phase 3Active
- Sponsor
- Novartis
- Start
- Oct 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of canakinumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Novartis. Primary endpoint: Incidence of dose-limiting toxicities. Started Oct 2018; status: active.
02
Drugs
canakinumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2018-001547-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001547-32.